DBV Technologies | Date: 2012-10-12
The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen.
DBV Technologies | Date: 2013-02-04
The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.
News Article | October 13, 2015
Xtalks Provides Current Articles Daily in the Life Science Industry TORONTO, ON--(Marketwired - October 13, 2015) - Check out all news stories here: http://xtalks.com/News.ashx. Subscribe to our weekly newsletter: http://register.xtalks.com/newsblogs. Shares in DBV Up Following Release of Phase IIb Trial Data for Peanut Allergy Drug - http://ow.ly/Tdjj7 (Oct 9) DBV Technologies stocks rose by as much as 13 percent after the company released promising Phase IIb clinical trial data, for its peanut allergy therapy. Hands-Free Smartphone Device Could Improve Vein Location for Injection Administration - http://ow.ly/Tdjr4 (Oct 9) A 3-D printed smartphone device fitted with an infrared-filtered lens, has been developed by researchers at Nottingham Trent University in the UK. Study Finds Flaw in GC-MS Analysis of Small Molecules - http://ow.ly/TdjBK (Oct 8) Research conducted at The Scripps Research Institute (TSRI), has identified a fundamental flaw in a common laboratory technique: gas chromatography mass spectrometry (GC-MS) changes the small molecule samples, as it performs its analysis. Relationship Between Big Data and Big Pharma Mutually Beneficial, Says Roche CEO - http://ow.ly/TdjHd (Oct 8) According to Roche's CEO, Severin Schwan, Big Pharma should strive to form digital partnerships in order to harness the potential of Big Data. Trans-Pacific Partnership and Drug Patent Exclusivity - http://ow.ly/TdjLy (Oct 7) Though the US representatives argued in favour of a 12-year patent protection policy -- the current term of a drug patent in the country -- they faced opposition from the other nations involved in the talks. Role of Sugars in Antibody Function - http://ow.ly/TdjUb (Oct 7) Research conducted at the University of Zurich has now identified that a specific sugar -- sialic acid -- is key to protecting host cells from attack by antibodies. Exposure to Beneficial Bacteria May Prevent Asthma in Children - http://ow.ly/TdjZw (Oct 6) Three month old children who are missing four beneficial strains of bacteria appear to face a heightened chance of developing asthma at age three. Drugs That Give Same Health Benefits as Exercise Could Be in the Pipeline - http://ow.ly/TdkbU (Oct 5) Exercise isn't always a viable treatment option, so developing drugs that mimic the effects may be a new way forward. Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com.
News Article | September 11, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l6pzmr/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Partial list of the 70+ companies mentioned in this comprehensive report:
News Article | June 4, 2015
The report “Eosinophilic Esophagitis – Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis. Eosinophilic esophagitis is a chronic immune system disease. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Eosinophilic Esophagitis with 24 market data tables and 14 figures, spread across 67 pages is available at http://www.rnrmarketresearch.com/eosinophilic-esophagitis-pipeline-review-h1-2015-market-report.html . Companies discussed in this Eosinophilic Esophagitis – Pipeline Review, H1 2015 report include Actavis plc, DBV Technologies S.A., Dr. Falk Pharma GmbH, Lipella Pharmaceuticals, Inc., Novartis AG, Oxagen Limited, Receptos, Inc., Regeneron Pharmaceuticals, Inc., Shire Plc, Teva Pharmaceutical Industries Limited. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Drug Profiles mentioned in this report are Allergen for Milk Allergy, budesonide, budesonide, dupilumab, EUR-1100, OC-459, QAX-576, reslizumab, RPC-4046, tacrolimus liposomal. Featured News & Press Releases covered by this report includes: Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis; Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients; Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis; May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children; Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis; May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis; May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis; Nov 23, 2009: Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388761 . (This is a premium report priced at US$2000 for a single user License.) List of Tables Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8 Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Eosinophilic Esophagitis - Pipeline by Actavis plc, H1 2015 15 Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H1 2015 16 Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 17 Eosinophilic Esophagitis - Pipeline by Lipella Pharmaceuticals, Inc., H1 2015 18 Eosinophilic Esophagitis - Pipeline by Novartis AG, H1 2015 19 Eosinophilic Esophagitis - Pipeline by Oxagen Limited, H1 2015 20 Eosinophilic Esophagitis - Pipeline by Receptos, Inc., H1 2015 21 Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 22 Eosinophilic Esophagitis - Pipeline by Shire Plc, H1 2015 23 Eosinophilic Esophagitis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 24 Assessment by Monotherapy Products, H1 2015 25 Number of Products by Stage and Target, H1 2015 27 Number of Products by Stage and Mechanism of Action, H1 2015 29 Number of Products by Stage and Route of Administration, H1 2015 31 Number of Products by Stage and Molecule Type, H1 2015 33 Eosinophilic Esophagitis Therapeutics - Recent Pipeline Updates, H1 2015 50 Eosinophilic Esophagitis - Dormant Projects, H1 2015 58 List of Figures Number of Products under Development for Eosinophilic Esophagitis, H1 2015 8 Number of Products under Development for Eosinophilic Esophagitis - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Products, H1 2015 13 Assessment by Monotherapy Products, H1 2015 25 Number of Products by Top 10 Targets, H1 2015 26 Number of Products by Stage and Top 10 Targets, H1 2015 27 Number of Products by Top 10 Mechanism of Actions, H1 2015 28 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29 Number of Products by Top 10 Routes of Administration, H1 2015 30 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31 Number of Products by Top 10 Molecule Types, H1 2015 32 Number of Products by Stage and Top 10 Molecule Types, H1 2015 33 Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . About Us: RnRMarketResearch.com is an online database of market research reports and offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offers customized market research reports for multiple industries.